Skip to content

Point-of-Care C-reactive protein to assist in primary care management of children with lower respiratory tract infection

Point-of-Care C-reactive protein to assist in primary care management of children with lower respiratory tract infection - PRICE

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON41688
Enrollment
354
Registered
2013-12-24
Start date
2014-01-28
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute bronchitus cough Lower Respiratory Tract Infections (LRTI)

Interventions

GP practices are randomised to usual care, or usual care plus POC CRP. 22 practices from three different regions in the Netherlands will be involved (Utrecht, Rotterdam and Maastricht). Children can

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
2 Years to 11 Years

Inclusion criteria

Inclusion criteria: - Children aged between 3 months and 12 years presenting to the GP with a non-severe LRTI. - LRTI will be defined as acute cough (shorter than 21 days) with (reported) fever (>38 °C). - The parent of the patient should be able to provide written informed consent and be willing to (help to) complete the patient diary.

Exclusion criteria

Exclusion criteria: - immunodeficiency - recent (previous four weeks) use of systemic antibiotics and/or corticosteroids - being severely ill as judged by the GP based on symptoms and signs - highly suspected of having pneumonia;Being severely ill or highly suspected of pneumonia includes: signs of dehydration, cyanosis, tachypnoe, lower level of consciousness or fever during > 5 days, no food or fluid intake, or otherwise judged as being severely ill by the GP.

Design outcomes

Primary

MeasureTime frame
The primary outcome is the % antibiotic prescriptions during 28 days after first consultation.

Secondary

MeasureTime frame
Secondary outcomes include health care use, costs, adverse events, quality of life (QOL), symptoms, and cost-effectiveness.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)